The fact that targeting of TLR7 agonists to FRβ+ TAMs/MDSCs leads to a significant reduction in tumor growth (17) suggests that FRβ+ TAMs/MDSCs are naturally immunosuppressive. The gene discussed is TLR7; the disease is neoplasm.